Precipio

Precipio reported record revenue of $7.0m in Q2 2025 (+22.8% y/y), positive adjusted EBITDA of $400,000 and operating cash flow of $700,000. Product revenue rose sequentially by 36.4% to $900,000; the company closed with $3.0m in cash without a capital raise. Management highlights interest in the Rapid AML Panel, expansion of distribution partnerships and further revenue growth in H2 2026, but gives no short-term guidance. » More on de.investing.com

Precipio urges shareholders to submit their broker voting instructions by Saturday 11:59 p.m. Eastern Time so the annual general meeting scheduled for Sunday at 10:00 a.m. is quorate. As of Friday participation stood at around 42 percent, while a quorum of at least 50 percent is required; failure would lead to an adjournment and additional costs. The company, which develops products for cancer diagnostics, asks all shareholders, regardless of voting intent, to vote so their holdings are counted in the quorum calculation. » More on de.investing.com

Precipio reported Q4 2025 revenue of $6.7 million and earnings per share of $0.29, and reached positive cash flow for the first time in 2025. Annual revenue rose 30% to $24 million, and the gross margin improved from 41% to 45%. Despite the financial turnaround, the stock fell 3.74% after the announcement and saw mixed investor reactions. Management plans to expand the product business and the sales team in 2026, but remains focused on risks in the product division, the supply chain and the competitive environment. » More on de.investing.com